Executive Summary
Across the 25 filings in this S&P 500 Healthcare stream, the dominant theme is a sharp divergence between top-line growth and earnings quality.
AbbVie (+10.3% Q3 revenue) and Vertex (+11.8% Q3 revenue) grew strongly, while Pfizer (-0.4%) and UnitedHealth (-0.4%) were flat to down on revenue, and Amgen's reported 8% growth masked steep erosion in its biosimilar-exposed franchises (Prolia -45%, XGEVA -47%). Earnings optics are heavily distorted by one-time items: Pfizer's nine-month net income fell 39.7% on $4.5B of impairments, AbbVie's Q3 earnings jumped on lapping a $2.7B prior-year IPR&D charge, and UnitedHealth's operating earnings rose 52% on improved medical cost trends. Operating expense growth outpaced revenue at several companies, with R&D up 18% at Pfizer and 35% at Vertex and SG&A up 62% at Vertex following the ~$9.1B Crinetics acquisition, which pushed Vertex's cash down from ~$12.3B to ~$9.8B. Capital structure is shifting toward leverage: AbbVie raised $17.97B in new long-term debt and Vertex took on a $4.5B term loan, while Amgen repurchased no shares and free cash flow fell to $3.7B. Insider activity was dominated by routine compensation-related withholding and 10b5-1 plan sales, with notable Regeneron director and Eli Lilly executive sales; Pfizer's appointment of a permanent CFO and a raised full-year guidance range are the clearest positive corporate developments.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · 10-Q · Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from November 02, 2026.
Investment Signals (10)
- Pfizer ↓ (BULLISH)▲
Raised FY2026 revenue guidance by $1.5B at midpoint to $62.0-$64.0B and narrowed Adjusted EPS guidance to $2.95-$3.05; ex-Comirnaty/Paxlovid revenue grew 7% operationally and Launched/Acquired Products grew 32%
- AbbVie ↓ (BULLISH)▲
Q3 2026 net revenue +10.3% YoY to $17.4B and nine-month revenue +10.9%; Q3 diluted EPS rose to $2.37 from $0.10 on lapping a $2.68B prior-year IPR&D charge
- Vertex Pharmaceuticals ↓ (BEARISH)▲
Q3 revenue +11.8% YoY to $3.44B, but net income -39.6% and SG&A +61.8% post-Crinetics deal; execution on the ~$9.1B acquisition is the key variable
- UnitedHealth Group ↓ (BULLISH)▲
Nine-month diluted EPS +32.5% to $17.50 and operating cash flow +34.9% to $25.1B, with medical costs down 2.6% YoY, signaling margin recovery despite flat revenue
- Amgen ↓ (BULLISH)▲
Q3 revenue +8% and GAAP EPS +19%, with strong growth in Repatha (+37%), EVENITY (+39%), UPLIZNA (+191%), and IMDELLTRA (+128%) offsetting biosimilar erosion
- Amgen ↓ (BEARISH)▲
Prolia volume -23% and no share repurchases in the quarter, with free cash flow down to $3.7B from $4.2B, reducing near-term shareholder return capacity
- Eli Lilly ↓ (BEARISH)▲
EVP & GC Anat Hakim sold 5,000 shares at $1,402.52 (~$7.0M) under a 10b5-1 plan, while multiple executives' activity was limited to tax withholding on vesting RSUs at $1,417.54
- Regeneron ↓ (BEARISH)▲
Director Michael Brown sold 1,929 shares at $875 (~$1.69M) and Director Kathryn Guarini sold 400 shares at $900 under 10b5-1 plans; both exercised options at lower strike prices first
- Pfizer ↓ (BULLISH)▲
Board appointed Cecile Guegan as permanent CFO effective Nov 1, 2026 after serving as interim since Aug 16, ending leadership uncertainty in finance functions
- Bristol Myers Squibb ↓ (BULLISH)▲
CEO Christopher Boerner acquired 406 shares alongside tax withholding on 1,724 shares at $62.48, a small but net-positive open-market signal
Risk Flags (9)
- Pfizer/Impairments↓ [HIGH RISK]▼
$4.49B of nine-month asset write-offs and impairments drove a 39.7% fall in net income to $5.7B and a $4.87B other expense line versus $2.21B a year earlier
- Amgen/Biosimilar Erosion↓ [HIGH RISK]▼
Prolia (-45%) and XGEVA (-47%) declines plus Otezla (-18%) and TAVNEOS (-2%, FDA engagement ongoing) point to accelerating pricing and volume pressure in legacy franchises
- Vertex/Earnings Quality↓ [HIGH RISK]▼
Diluted EPS fell 39% to $2.56 despite 11.8% revenue growth as SG&A (+61.8%) and R&D (+35%) outran sales; interest expense rose to $36M from $3.3M on the new term loan
- AbbVie/Expense Growth↓ [MEDIUM RISK]▼
Quarterly SG&A +14.5% and R&D +10.7% and other expense, net +41.1% in Q3 to $738M, while interest expense rose to $700M, eroding operating leverage
- UnitedHealth/Balance Sheet & Mix↓ [MEDIUM RISK]▼
Accumulated other comprehensive loss widened to $(3.9)B from $(2.1)B on unrealized investment losses, and premium revenue fell about 2.1% YoY as mix shifted to products and services
- Pfizer/Expense Pressure↓ [MEDIUM RISK]▼
Q3 R&D +18.4% to $3.0B and SG&A +2.9%, with a $650M one-time Innovent acquired IPR&D charge pressuring reported results
- Vertex/Liquidity↓ [MEDIUM RISK]▼
Cash and marketable securities declined ~$2.5B YTD to ~$9.8B while total debt rose to ~$4.5B, reducing financial flexibility for further M&A
- Regeneron/Insider Selling Cluster↓ [MEDIUM RISK]▼
Multiple director and executive sales under 10b5-1 plans at ~$875-$900 per share within the same reporting window, though none are large relative to holdings
- AbbVie/Debt Financing↓ [MEDIUM RISK]▼
$17.97B of new long-term debt issuance in the period, with cash balances rising to $10.8B from $5.2B, raising questions about the use of proceeds and future leverage
Opportunities (7)
- Pfizer/Guidance Momentum↓ (OPPORTUNITY)◆
Raised FY2026 revenue and narrowed EPS guidance despite a $650M Innovent IPR&D charge; ex-COVID products growing 7% operationally signals underlying recovery
- AbbVie/Earnings Normalization↓ (OPPORTUNITY)◆
Reported EPS of $2.37 in Q3 benefits from lapping a $2.68B prior-year IPR&D charge; underlying revenue growth of ~10% supports a re-rating if expenses are contained
- UnitedHealth/Margin Recovery↓ (OPPORTUNITY)◆
Operating earnings +52% in Q3 and nine-month operating cash flow +34.9% to $25.1B show the medical cost reset is converting to cash, with diluted EPS up 32.5% year-to-date
- Amgen/Growth Franchise Ramp↓ (OPPORTUNITY)◆
UPLIZNA (+191%), IMDELLTRA (+128%), EVENITY (+39%), and Repatha (+37%) are offsetting biosimilar declines; Nplate ex-U.S. government orders +11% vs. 3% reported
- Vertex/Crinetics Integration Upside↓ (OPPORTUNITY)◆
Completed ~$9.1B acquisition effective Sept 1, 2026; if pipeline synergies materialize, the post-deal expense base could be justified by revenue growth of ~11%
- Pfizer/Management Stability↓ (OPPORTUNITY)◆
Permanent CFO Cecile Guegan, who previously led enterprise acquisitions and integrations, reduces execution risk on the acquisition pipeline and capital allocation
- Bristol Myers Squibb/Insider Alignment↓ (OPPORTUNITY)◆
CEO open-market purchase of 406 shares alongside routine vesting activity signals management confidence at current prices of ~$62
Sector Themes (6)
- Revenue Growth Dispersion◆
Q3 2026 revenue changes ranged from -0.4% (Pfizer, UnitedHealth) to +11.8% (Vertex); AbbVie (+10.3%) and Amgen (+8%) sit at the high end, indicating growth is concentrated in launch-stage and specialty franchises [Implication: favor companies with launched-product momentum over legacy portfolios]
- Biosimilar and Pricing Pressure on Legacy Franchises◆
Amgen's Prolia (-45%) and XGEVA (-47%), Pfizer's product revenue declines, and Otezla (-18%) all show erosion, with Amgen attributing part of the decline to net selling price and sales deductions [Implication: legacy-heavy portfolios face sustained margin pressure through 2027]
- Acquisition-Driven Expense Inflation and Leverage◆
Vertex's ~$9.1B Crinetics deal (SG&A +62%, debt ~$4.5B), AbbVie's $18B debt issuance, and Pfizer's $650M Innovent IPR&D charge show a sector-wide pattern of debt-funded deals that depress near-term EPS [Implication: investors should discount reported EPS for IPR&D and integration costs]
- Impairment and One-Time Charge Distortion◆
Pfizer's $4.5B impairments, AbbVie's prior-year $2.7B IPR&D charge, and the 2025 comparison base distort year-over-year net income by 30-40 points; adjusted metrics are essential for comparison [Implication: GAAP-to-adjusted gaps are unusually wide this period]
- Shareholder Return Moderation◆
Amgen repurchased no shares in Q3 with FCF down 12%, while Vertex and AbbVie prioritized deal funding and debt; buybacks appear to be deferred across large-cap biopharma [Implication: dividend-led total return thesis more reliant on yield than buyback accretion]
- Insider Activity Dominated by Compensation Mechanics◆
Most of the 25 filings reflect tax withholding on RSU/PSU vesting, phantom stock awards, and gifts; open-market sales are concentrated at Eli Lilly (Hakim $7.0M), and Regeneron directors under 10b5-1 plans, with no cluster of sales across the sector [Implication: insider signals are weak in aggregate and should not drive positioning alone]
Watch List (8)
-
Monitor expense trajectory and quarterly cash burn after the ~$9.1B deal closed Sept 1, 2026; next earnings will show whether SG&A normalizes from +61.8% [Next quarterly report]
-
Track Q4 execution against raised revenue guidance of $62.0-$64.0B and Adjusted EPS $2.95-$3.05 following the Innovent IPR&D charge and impairment cycle [Next quarterly report]
-
Company is continuing regulatory engagement after TAVNEOS sales fell 2% on volume and sales-deduction changes; any FDA labeling or pricing action is a near-term catalyst [Ongoing]
-
Watch how the $18B of new debt is deployed (M&A, buybacks, or working capital) given cash rose to $10.8B and interest expense climbed to $700M in Q3 [Next quarterly report]
-
Confirm that the 2.6% decline in nine-month medical costs persists and that the premium decline of ~2.1% does not accelerate, as this drives the margin thesis [Next quarterly report]
-
Monitor further 10b5-1 sales by directors Brown and Guarini following option exercises around $875-$900 for signs of broader insider de-risking [Ongoing]
-
Guegan's permanent appointment took effect Nov 1, 2026; watch for any changes to capital allocation priorities, impairment policy, or the acquisition pipeline under new leadership [Ongoing]
-
Track whether share repurchases resume after the zero-buyback quarter and whether free cash flow recovers from $3.7B toward the prior $4.2B run rate [Next quarterly report]
Filing Analyses
(25)
03-11-2026
Amgen reported third quarter 2026 total revenues up 8% year-over-year to $10.4 billion, with GAAP EPS up 19% to $7.08 and non-GAAP EPS up 14% to $6.45. Performance was mixed across the portfolio: Repatha (+37%), EVENITY (+39%), UPLIZNA (+191%), and IMDELLTRA (+128%) grew strongly, while Prolia (-45%), XGEVA (-47%), Otezla (-18%), and TAVNEOS (-2%) declined as biosimilar competition and pricing pressure weighed. Free cash flow fell to $3.7 billion from $4.2 billion, and no shares were repurchased in the quarter.
- · Nplate growth excluding U.S. government orders was 11% YoY, versus 3% reported
- · Prolia volume fell 23%, with the remainder of the decline split between net selling price and sales deductions
- · TAVNEOS sales declined 2% on 9% lower volume and 8% unfavorable sales deduction changes; Amgen states it continues to engage with the FDA
- · Enbrel sales were pressured by 14% lower net selling price tied to Medicare Part D price setting under the Inflation Reduction Act effective 2026
- · Total operating expenses fell 5% GAAP, largely due to lower amortization of acquisition-related assets, while non-GAAP operating expenses rose 8%
- · Dividends paid were $1.4B in Q3 2026 and no share repurchases occurred during the quarter
- · Q3 2026 dividend of $2.52 per share was a 6% increase over the prior year period
03-11-2026
Pfizer reported Q3 2026 total revenues of $16,583 Million, down 0.4% YoY from $16,654 Million, while net income attributable to Pfizer shareholders fell 8.4% to $3,242 Million from $3,541 Million. Nine-month revenues rose 2.3% to $46,067 Million, but nine-month net income fell 39.7% to $5,681 Million, largely reflecting $4,487 Million of asset write-offs and impairments and a $1,870 Million gain on the ViiV investment sale. Mixed performance: product revenues declined while alliance and royalty revenues grew.
- · Q3 2026 Selling, informational and administrative expenses rose 2.9% to $3,279 Million and R&D expenses rose 18.4% to $3,016 Million, compressing operating margins.
- · Q3 2026 Other (income)/deductions was an expense of $288 Million versus $517 Million a year earlier, while nine-month Other (income)/deductions was an expense of $4,866 Million versus $2,210 Million, driven by impairments.
- · Q3 2026 effective tax provision was $134 Million versus a $216 Million benefit in Q3 2025; nine-month provision was $188 Million versus a $264 Million benefit.
- · Q3 2026 acquired IPR&D expense fell to $669 Million from $1,390 Million, and amortization of intangibles declined to $1,128 Million from $1,223 Million.
- · Cash dividends paid were $7,347 Million for nine months, roughly in line with $7,326 Million a year earlier; no dividends payable were outstanding at September 27, 2026 versus $2,445 Million at year-end 2025.
- · Trade accounts receivable rose to $14,192 Million from $11,874 Million at year-end 2025, a 19.5% increase, while inventories declined to $10,022 Million from $10,654 Million.
- · Long-term debt declined to $59,997 Million from $61,641 Million, and nine-month payments on long-term debt were $1,250 Million; short-term borrowings fell to $2,674 Million from $3,154 Million.
- · Cash and cash equivalents rose to $1,824 Million from $1,142 Million at year-end 2025.
- · Pfizer's shareholders' equity increased to $89,001 Million from $86,476 Million, supported by $5,681 Million of net income and $1,100 Million of OCI, net of $4,902 Million of dividends.
- · Q3 2026 comprehensive income attributable to Pfizer was $3,491 Million versus $3,913 Million a year earlier.
03-11-2026
AbbVie reported Q3 2026 net revenues of $17,404 million, up 10.3% from $15,776 million in Q3 2025, and nine-month revenues of $49,396 million, up 10.9% from $44,542 million. Q3 net earnings attributable to AbbVie rose sharply to $4,218 million ($2.37 diluted EPS) from $186 million ($0.10) a year earlier, largely because Q3 2025 carried $2,680 million of acquired IPR&D and milestone charges versus $216 million in 2026. However, quarterly SG&A rose 14.5% to $4,087 million and R&D rose 10.7% to $2,567 million, and other expense, net for the nine months was essentially flat at $4,519 million versus $4,630 million.
- · Interest expense, net rose to $700 million in Q3 2026 from $667 million, and to $2,024 million for nine months from $1,972 million.
- · Other expense, net rose 41.1% in Q3 2026 to $738 million from $523 million, even as the nine-month figure declined slightly.
- · Cash and equivalents rose to $10,774 million from $5,229 million at year-end 2025, driven by $17,974 million of new long-term debt issuance.
- · Long-term debt increased to $72,230 million from $58,941 million at December 31, 2025, while total stockholders' deficit widened to $(4,583) million from $(3,270) million.
- · Acquisitions of businesses consumed $10,594 million in cash for the nine months versus $204 million a year earlier.
- · Dividends declared were $3,075 million in Q3 2026, and dividends paid totaled $9,227 million for the nine months.
03-11-2026
UnitedHealth Group's Q3 2026 10-Q shows third-quarter revenue of $112,694 Million, down 0.4% YoY from $113,161 Million, while earnings from operations rose 52.1% to $6,563 Million and diluted EPS increased to $4.56 from $2.59. Nine-month revenue grew 0.6% to $336,447 Million, but nine-month diluted EPS of $17.50 was up 32.5% from $13.21, and medical costs were down 2.6% YoY for the nine months, reflecting margin improvement. Total equity rose to $104,129 Million, though accumulated other comprehensive loss widened to $(3,934) Million from $(2,061) Million at year-end 2025.
- · Q3 2026 premiums fell about 2.1% YoY while products revenue rose about 7.6% and services revenue rose about 5.1%, showing mix shift away from premium revenue
- · Accumulated other comprehensive loss widened to $(3934) Million from $(2061) Million at December 31, 2025, driven by unrealized losses on investments
- · Nine-month operating cash flow rose to $25087 Million from $18589 Million, a 34.9% increase YoY
- · Nine-month share repurchases of $5147 Million and dividends of $6170 Million were both higher than the prior-year period in dividends
- · Total debt declined: long-term debt fell to $68714 Million from $72320 Million at year-end 2025, and nine-month debt repayments were $3650 Million
03-11-2026
Vertex Pharmaceuticals reported Q3 2026 total revenues of $3,440.8M, up 11.8% YoY from $3,076.4M, and nine-month revenues of $9,761.6M, up 10.8% from $8,811.3M. However, net income fell 39.6% YoY to $653.6M for the quarter, driven by a 61.8% jump in SG&A to $844.1M and a 35.0% rise in R&D to $1,320.6M, and diluted EPS declined 39.0% to $2.56. The company completed the ~$9.1B cash acquisition of Crinetics Pharmaceuticals (effective September 1, 2026), funded partly by a $4.5B term loan, leaving total debt of ~$4.5B.
- · Cash and cash equivalents plus marketable securities (short and long-term) totaled ~$9.8B at September 30, 2026, down from ~$12.3B at December 31, 2025.
- · Q3 2026 SG&A rose to $844.1M from $445.1M, with the increase linked to acquisition-related and commercial activity; Q3 2026 interest expense rose to $36.0M from $3.3M reflecting the new term loan.
- · Q3 2026 comprehensive income fell to $662.3M from $1,119.5M; accumulated other comprehensive income swung to $57.2M from $(15.9)M at year-end 2025.
- · Goodwill rose to $2,423.4M from $1,088.0M and other intangibles to $8,517.8M from $424.2M, reflecting the Crinetics acquisition and resulting in a large increase in intangible-asset concentration.
- · Deferred tax assets declined to $1,952.9M from $2,897.9M; nine-month deferred income tax benefit was $(319.7)M versus $(541.3)M prior year.
- · Nine-month 2025 included a $379.0M intangible asset impairment charge with no equivalent in 2026.
- · Nine-month 2026 cash paid for income taxes was $803.2M versus $1,177.3M in the prior-year period.
03-11-2026
Director BROWN MICHAEL S sold 1,929 Common Stock at $875.00 (~$1.69M). BROWN MICHAEL S holds 1,380 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director BROWN MICHAEL S exercised/converted 1,929 Common Stock at $725.89 (~$1.4M)
- · Director BROWN MICHAEL S sold 1,929 Common Stock at $875.00 (~$1.69M)
- · Director BROWN MICHAEL S exercised/converted 1,929 Non-Qualified Stock Option (right to buy)
03-11-2026
EVP Commercial McCourt Marion sold 1,132 Common Stock at $869.43 (~$984K). McCourt Marion holds 10,871 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP Commercial McCourt Marion sold 1,132 Common Stock at $869.43 (~$984K)
03-11-2026
Pfizer announced that its Board of Directors unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, having served as interim CFO since August 16, 2026. She will oversee all corporate finance functions, including audit, treasury, investor relations, tax, insurance, OP&A, controllership, and business finance and analytics. The filing contains no period-over-period financial results, so no performance metrics are reported.
- · Guegan previously was directly responsible for financial operations and reporting of Pfizer's biopharmaceutical business across all therapeutic areas and geographies
- · Guegan previously led major enterprise acquisitions and integrations and co-led a strategic initiative to identify new sources of growth
- · Guegan holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF)
- · Guegan's stated capital allocation focus is disciplined capital allocation alongside targeted investments to drive revenue growth later in the decade
03-11-2026
EVP, Chief Digital & Tech Off. Meyers Gregory Scott had withheld for taxes 2,665 Common Stock, $0.10 par value at $62.48 (~$167K). Meyers Gregory Scott holds 33,977 shares after the transaction.
- · EVP, Chief Digital & Tech Off. Meyers Gregory Scott exercised/converted 6,281 Common Stock, $0.10 par value
- · EVP, Chief Digital & Tech Off. Meyers Gregory Scott had withheld for taxes 2,665 Common Stock, $0.10 par value at $62.48 (~$167K)
- · EVP, Chief Digital & Tech Off. Meyers Gregory Scott exercised/converted 6,281 Restricted Stock Units
03-11-2026
EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 Common Stock. Skovronsky Daniel holds 159,952.725 shares after the transaction.
- · EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 Common Stock
03-11-2026
EVP, GC & Secretary Hakim Anat sold 5,000 Common Stock at $1,402.52 (~$7.01M). Hakim Anat holds 4,137.456 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP, GC & Secretary Hakim Anat sold 5,000 Common Stock at $1,402.52 (~$7.01M)
03-11-2026
EVP & CFO Montarce Lucas had withheld for taxes 677.593 Common Stock at $1,417.54 (~$961K). Montarce Lucas holds 17,190.88 shares after the transaction.
- · EVP & CFO Montarce Lucas exercised/converted 1,610 Common Stock
- · EVP & CFO Montarce Lucas had withheld for taxes 677.593 Common Stock at $1,417.54 (~$961K)
- · EVP & CFO Montarce Lucas exercised/converted 1,610 Restricted Stock Unit
03-11-2026
EVP & Pres., Mfg. Operations Hernandez Edgardo had withheld for taxes 1,122.902 Common Stock at $1,417.54 (~$1.59M). Hernandez Edgardo holds 47,489.815 shares after the transaction.
- · EVP & Pres., Mfg. Operations Hernandez Edgardo exercised/converted 2,530 Common Stock
- · EVP & Pres., Mfg. Operations Hernandez Edgardo had withheld for taxes 1,122.902 Common Stock at $1,417.54 (~$1.59M)
- · EVP & Pres., Mfg. Operations Hernandez Edgardo exercised/converted 2,530 Restricted Stock Unit
03-11-2026
EVP, Chief People Officer Dozier Eric had withheld for taxes 1,019.361 Common Stock at $1,417.54 (~$1.44M). Dozier Eric holds 15,519.851 shares after the transaction.
- · EVP, Chief People Officer Dozier Eric exercised/converted 2,300 Common Stock
- · EVP, Chief People Officer Dozier Eric had withheld for taxes 1,019.361 Common Stock at $1,417.54 (~$1.44M)
- · EVP, Chief People Officer Dozier Eric exercised/converted 2,300 Restricted Stock Unit
03-11-2026
EVP & President, Card Met Hlth Custer Kenneth L. had withheld for taxes 1,425.447 Common Stock at $1,417.54 (~$2.02M). Custer Kenneth L. holds 11,935.097 shares after the transaction.
- · EVP & President, Card Met Hlth Custer Kenneth L. exercised/converted 3,220 Common Stock
- · EVP & President, Card Met Hlth Custer Kenneth L. had withheld for taxes 1,425.447 Common Stock at $1,417.54 (~$2.02M)
- · EVP & President, Card Met Hlth Custer Kenneth L. exercised/converted 3,220 Restricted Stock Unit
03-11-2026
EVP, President LLY Imm Brown Adrienne S had withheld for taxes 1,098.656 Common Stock at $1,417.54 (~$1.56M). Brown Adrienne S holds 9,893.923 shares after the transaction.
- · EVP, President LLY Imm Brown Adrienne S exercised/converted 2,530 Common Stock
- · EVP, President LLY Imm Brown Adrienne S had withheld for taxes 1,098.656 Common Stock at $1,417.54 (~$1.56M)
- · EVP, President LLY Imm Brown Adrienne S exercised/converted 2,530 Restricted Stock Unit
03-11-2026
EVP, Chief Supply Chain & Ops Shanahan Karin had withheld for taxes 3,213 Common Stock, $0.10 par value at $62.48 (~$201K). Shanahan Karin holds 28,956 shares after the transaction.
- · EVP, Chief Supply Chain & Ops Shanahan Karin exercised/converted 6,281 Common Stock, $0.10 par value
- · EVP, Chief Supply Chain & Ops Shanahan Karin had withheld for taxes 3,213 Common Stock, $0.10 par value at $62.48 (~$201K)
- · EVP, Chief Supply Chain & Ops Shanahan Karin exercised/converted 6,281 Restricted Stock Units
03-11-2026
Director Guarini Kathryn sold 400 Common Stock at $900.00 (~$360K). Guarini Kathryn holds 603 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director Guarini Kathryn exercised/converted 400 Common Stock at $719.37 (~$288K)
- · Director Guarini Kathryn sold 400 Common Stock at $900.00 (~$360K)
- · Director Guarini Kathryn exercised/converted 400 Non-Qualified Stock Option (right to buy)
03-11-2026
Director Stetter Mark was awarded 5.8516 Phantom Stock Unit at $79.72 (~$466).
- · Director Stetter Mark was awarded 5.8516 Phantom Stock Unit at $79.72 (~$466)
03-11-2026
Chief Executive Officer BOERNER CHRISTOPHER S. had withheld for taxes 1,724 Common Stock, $0.10 par value at $62.48 (~$108K). 4 transactions reported in total. BOERNER CHRISTOPHER S. holds 23,097 shares after the transaction.
- · Chief Executive Officer BOERNER CHRISTOPHER S. exercised/converted 2,964 Common Stock, $0.10 par value
- · Chief Executive Officer BOERNER CHRISTOPHER S. acquired 406 Common Stock, $0.10 par value
- · Chief Executive Officer BOERNER CHRISTOPHER S. had withheld for taxes 1,724 Common Stock, $0.10 par value at $62.48 (~$108K)
- · Chief Executive Officer BOERNER CHRISTOPHER S. exercised/converted 2,964 Market Share Units
03-11-2026
Director DIAZ PAUL J was awarded 613.073 Phantom Stock at $149.52 (~$91.7K).
- · Director DIAZ PAUL J was awarded 613.073 Phantom Stock at $149.52 (~$91.7K)
03-11-2026
SVP, Chief HR Officer O'Sullivan Miriam had withheld for taxes 1,872 Common Stock at $41.98 (~$78.6K). O'Sullivan Miriam holds 19,565 shares after the transaction.
- · SVP, Chief HR Officer O'Sullivan Miriam exercised/converted 3,871 Common Stock
- · SVP, Chief HR Officer O'Sullivan Miriam had withheld for taxes 1,872 Common Stock at $41.98 (~$78.6K)
- · SVP, Chief HR Officer O'Sullivan Miriam exercised/converted 3,871 Restricted Stock Units
03-11-2026
Director HOOLEY JOSEPH L was awarded 48 Common Stock at $551.21 (~$26.5K). HOOLEY JOSEPH L holds 373 shares after the transaction.
- · Director HOOLEY JOSEPH L was awarded 48 Common Stock at $551.21 (~$26.5K)
03-11-2026
Pfizer reported Q3 2026 revenues of $16.6 billion, relatively flat year-over-year (down $71 million, or about flat on a percentage basis; operationally down $57 million), while excluding Comirnaty and Paxlovid, revenues grew 7% operationally and Launched and Acquired Products grew 32% operationally. Reported diluted EPS was $0.56 (down 9%) and Adjusted diluted EPS was $0.87 (flat). The company raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0-$64.0 billion and raised and narrowed Adjusted diluted EPS guidance to $2.95-$3.05, despite a one-time $650 million Acquired IPR&D charge tied to the Innovent Biologics deal.
- · Q3 Reported net income fell 8% to $3.2B and nine-month Reported net income fell 40% to $5.7B, driven by the prior-year 3SBio charge comparison and a higher effective tax rate
- · Q3 R&D expenses rose 18% operationally, reflecting higher oncology and obesity spending
- · Nine-month Adjusted diluted EPS declined 7% to $2.39 versus $2.56 a year earlier
- · No share repurchases were completed in 2026 and none are included in guidance; $3.3B authorization remains
- · Paxlovid (down 63%) and Comirnaty (down 29%) declines largely offset growth in Eliquis, Padcev and other launched products
- · Q3 Cost of Sales as a percentage of revenue improved to 24.3% from 25.0%
03-11-2026
Chairman & CEO BOURLA ALBERT was awarded 20 Phantom Stock Units SSP at $30.52 (~$610).
- · Chairman & CEO BOURLA ALBERT was awarded 20 Phantom Stock Units SSP at $30.52 (~$610)
Get daily alerts with 10 investment signals, 9 risk alerts, 7 opportunities and full AI analysis of all 25 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →November 03, 2026
US Pre-Market SEC Filings Roundup — November 03, 2026
US Pre-Market SEC Filings Roundup
November 03, 2026
US Corporate Board Director Changes SEC Filings — November 03, 2026
US Corporate Board Director Changes SEC Filings
November 03, 2026
US IPO Pipeline SEC S-1 Filings — November 03, 2026
US IPO Pipeline SEC S-1 Filings
November 03, 2026
US Merger & Acquisition SEC Filings — November 03, 2026
US Merger & Acquisition SEC Filings